Literature DB >> 25650184

Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women.

Lori S Tillmans1, Robert A Vierkant2, Alice H Wang2, Niloy Jewel Samadder3, Charles F Lynch4, Kristin E Anderson5, Amy J French1, Robert W Haile6, Lisa J Harnack5, John D Potter7, Susan L Slager2, Thomas C Smyrk1, Stephen N Thibodeau1, James R Cerhan8, Paul J Limburg9.   

Abstract

BACKGROUND: Cigarette smoking (smoking), hormone therapy (MHT), and folate intake (folate) are each thought to influence colorectal cancer risk, but the underlying molecular mechanisms remain incompletely defined. Expression of estrogen receptor β (ESR2) has been associated with colorectal cancer stage and survival.
METHODS: In this prospective cohort study, we examined smoking, MHT, and folate-associated colorectal cancer risks by ESR2 protein expression level among participants in the Iowa Women's Health Study (IWHS). Self-reported exposure variables were assessed at baseline. Archived, paraffin-embedded colorectal cancer tissue specimens were collected and evaluated for ESR2 protein expression by IHC. Multivariate Cox regression models were fit to estimate relative risks (RR) and 95% confidence intervals (CI) for associations between smoking, MHT, or folate and ESR2-defined colorectal cancer subtypes.
RESULTS: Informative environmental exposure and protein expression data were available for 491 incident colorectal cancer cases. Positive associations between ESR2-low and -high tumors and several smoking-related variables were noted, most prominently with average number of cigarettes per day (RR, 4.24; 95% CI, 1.81-9.91 for ESR2-low and RR, 2.15; 95% CI, 1.05-4.41 for ESR2-high for ≥40 cigarettes compared with nonsmokers). For MHT, a statistically significant association with ESR2-low tumors was observed with longer duration of exposure (RR, 0.54; 95% CI, 0.26-1.13 for >5 years compared with never use). No associations were found for folate.
CONCLUSIONS: In this study, smoking and MHT were associated with ESR2 expression patterns. IMPACT: These data support possible heterogeneous effects from smoking and MHT on ERβ-related pathways of colorectal carcinogenesis in older women. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25650184      PMCID: PMC4383694          DOI: 10.1158/1055-9965.EPI-14-0756

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  47 in total

Review 1.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

2.  Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.

Authors:  Wade S Samowitz; Hans Albertsen; Carol Sweeney; Jennifer Herrick; Bette J Caan; Kristin E Anderson; Roger K Wolff; Martha L Slattery
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

3.  Applying Cox regression to competing risks.

Authors:  M Lunn; D McNeil
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

4.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  Estrogen receptor beta is expressed in human colorectal adenocarcinoma.

Authors:  D Witte; M Chirala; A Younes; Y Li; M Younes
Journal:  Hum Pathol       Date:  2001-09       Impact factor: 3.466

6.  Colorectal cancer risk associated with hormone use varies by expression of estrogen receptor-β.

Authors:  Anja Rudolph; Csaba Toth; Michael Hoffmeister; Wilfried Roth; Esther Herpel; Peter Schirmacher; Hermann Brenner; Jenny Chang-Claude
Journal:  Cancer Res       Date:  2013-04-12       Impact factor: 12.701

7.  Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation.

Authors:  P A Konstantinopoulos; A Kominea; G Vandoros; G P Sykiotis; P Andricopoulos; I Varakis; G Sotiropoulou-Bonikou; A G Papavassiliou
Journal:  Eur J Cancer       Date:  2003-06       Impact factor: 9.162

8.  Expression of estrogen receptor beta in human colorectal cancer.

Authors:  Li-Qun Xie; Jie-Ping Yu; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

9.  Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.

Authors:  Paul J Limburg; David Limsui; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-15       Impact factor: 4.254

10.  Expression of oestrogen receptor β and prognosis of colorectal cancer.

Authors:  A Rudolph; C Toth; M Hoffmeister; W Roth; E Herpel; L Jansen; A Marx; H Brenner; J Chang-Claude
Journal:  Br J Cancer       Date:  2012-07-24       Impact factor: 7.640

View more
  7 in total

1.  Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.

Authors:  Sonja Neumeyer; Odilia Popanda; Dominic Edelmann; Katja Butterbach; Csaba Toth; Wilfried Roth; Hendrik Bläker; Ruijingfang Jiang; Esther Herpel; Cornelia Jäkel; Peter Schmezer; Lina Jansen; Elizabeth Alwers; Axel Benner; Barbara Burwinkel; Michael Hoffmeister; Hermann Brenner; Jenny Chang-Claude
Journal:  Epigenetics       Date:  2019-03-30       Impact factor: 4.528

Review 2.  Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.

Authors:  Tsuyoshi Hamada; NaNa Keum; Reiko Nishihara; Shuji Ogino
Journal:  J Gastroenterol       Date:  2016-10-13       Impact factor: 7.527

3.  Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine.

Authors:  Shuji Ogino; Reiko Nishihara; Tyler J VanderWeele; Molin Wang; Akihiro Nishi; Paul Lochhead; Zhi Rong Qian; Xuehong Zhang; Kana Wu; Hongmei Nan; Kazuki Yoshida; Danny A Milner; Andrew T Chan; Alison E Field; Carlos A Camargo; Michelle A Williams; Edward L Giovannucci
Journal:  Epidemiology       Date:  2016-07       Impact factor: 4.822

4.  Proceedings of the second international molecular pathological epidemiology (MPE) meeting.

Authors:  Shuji Ogino; Peter T Campbell; Reiko Nishihara; Amanda I Phipps; Andrew H Beck; Mark E Sherman; Andrew T Chan; Melissa A Troester; Adam J Bass; Kathryn C Fitzgerald; Rafael A Irizarry; Karl T Kelsey; Hongmei Nan; Ulrike Peters; Elizabeth M Poole; Zhi Rong Qian; Rulla M Tamimi; Eric J Tchetgen Tchetgen; Shelley S Tworoger; Xuehong Zhang; Edward L Giovannucci; Piet A van den Brandt; Bernard A Rosner; Molin Wang; Nilanjan Chatterjee; Colin B Begg
Journal:  Cancer Causes Control       Date:  2015-05-09       Impact factor: 2.506

Review 5.  Integration of molecular pathology, epidemiology and social science for global precision medicine.

Authors:  Akihiro Nishi; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Andy S Tan; Ichiro Kawachi; Shuji Ogino
Journal:  Expert Rev Mol Diagn       Date:  2015-12-04       Impact factor: 5.225

6.  Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer.

Authors:  Sonja Neumeyer; Barbara L Banbury; Volker Arndt; Sonja I Berndt; Stephane Bezieau; Stephanie A Bien; Dan D Buchanan; Katja Butterbach; Bette J Caan; Peter T Campbell; Graham Casey; Andrew T Chan; Stephen J Chanock; James Y Dai; Steven Gallinger; Edward L Giovannucci; Graham G Giles; William M Grady; Jochen Hampe; Michael Hoffmeister; John L Hopper; Li Hsu; Mark A Jenkins; Amit Joshi; Susanna C Larsson; Loic Le Marchand; Annika Lindblom; Victor Moreno; Mathieu Lemire; Li Li; Yi Lin; Kenneth Offit; Polly A Newcomb; Paul D Pharaoh; John D Potter; Lihong Qi; Gad Rennert; Clemens Schafmayer; Robert E Schoen; Martha L Slattery; Mingyang Song; Cornelia M Ulrich; Aung K Win; Emily White; Alicja Wolk; Michael O Woods; Anna H Wu; Stephen B Gruber; Hermann Brenner; Ulrike Peters; Jenny Chang-Claude
Journal:  Br J Cancer       Date:  2018-05-24       Impact factor: 7.640

7.  The peroxidase PRDX1 inhibits the activated phenotype in mammary fibroblasts through regulating c-Jun N-terminal kinases.

Authors:  Agnieszka Jezierska-Drutel; Shireen Attaran; Barbara L Hopkins; John J Skoko; Steven A Rosenzweig; Carola A Neumann
Journal:  BMC Cancer       Date:  2019-08-16       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.